Skip to Content
Upcoming Webinar

Discussion of Zanubrutinib for Adult Patients with CLL/SLL

Date: May 14, 2025 | 2:00 PM

May 14, 2025 | 2 p.m. EDT

Join NCODA for an in-depth clinical discussion with Dr. John Renshaw on the evolving role of zanubrutinib in the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

This session will explore the therapeutic positioning of zanubrutinib, including its use in patients who are intolerant to other BTK inhibitors, such as ibrutinib and acalabrutinib.

Key learning points include:

  • The clinical role of zanubrutinib in the current CLL/SLL treatment landscape

  • Efficacy and safety data from Study 215, with a focus on patients previously intolerant to ibrutinib and/or acalabrutinib

  • A comparative review of safety profiles between zanubrutinib and acalabrutinib using meta-analyses and matching-adjusted indirect comparisons (MAIC)

  • Dosing strategies and practical approaches to managing adverse events in everyday clinical practice

 

Login

 

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.

Sponsored by